Literature DB >> 20679439

Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility.

Anne L Bishop1, Stefan Schild, Bharathi Patimalla, Brian Klein, Andrew Camilli.   

Abstract

Vibrio cholerae is the causative agent of cholera, a severe diarrheal disease that remains endemic in many parts of the world and can cause outbreaks wherever sanitation and clean water systems break down. Prevention of disease could be achieved through improved sanitation and clean water provision supported by vaccination. V. cholerae serogroup O1 is the major cause of cholera; O1 serotypes Inaba and Ogawa have similar disease burdens, while O139 is the only non-O1 serogroup to cause epidemics. We showed previously that immunization of adult female mice with purified V. cholerae outer membrane vesicles (OMVs) elicits an antibody response that protect neonates from oral V. cholerae challenge and that suckling from an immunized dam accounts for the majority of protection from V. cholerae colonization. Here we report that lipopolysaccharide (LPS) is the major OMV protective antigen. Mucosal immunization with OMVs from Inaba or Ogawa provides significant cross-serotype protection from V. cholerae colonization, although serotype-specific antigens are dominant. OMVs from O1 or O139 do not provide cross-serogroup protection, but by immunization with a mixture of O1 and O139 OMVs, cross-serogroup protection was achieved. Neonatal protection is not associated with significant bacterial death but may involve inhibition of motility, as antibodies from OMV-immunized mice inhibit V. cholerae motility in vitro, with trends that parallel in vivo protection. Motility assays also reveal that a higher antibody titer is required to immobilize O139 compared to O1, a phenotype that is O139 capsule dependent.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679439      PMCID: PMC2950341          DOI: 10.1128/IAI.00398-10

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  83 in total

1.  Construction of an eae deletion mutant of enteropathogenic Escherichia coli by using a positive-selection suicide vector.

Authors:  M S Donnenberg; J B Kaper
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

2.  Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

Authors:  M M Levine; J B Kaper; D Herrington; G Losonsky; J G Morris; M L Clements; R E Black; B Tall; R Hall
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

3.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

Authors:  R M Horton; H D Hunt; S N Ho; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

4.  A novel suicide vector and its use in construction of insertion mutations: osmoregulation of outer membrane proteins and virulence determinants in Vibrio cholerae requires toxR.

Authors:  V L Miller; J J Mekalanos
Journal:  J Bacteriol       Date:  1988-06       Impact factor: 3.490

5.  Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin.

Authors:  R E Black; M M Levine; M L Clements; C R Young; A M Svennerholm; J Holmgren
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor.

Authors:  M Iwanaga; K Yamamoto; N Higa; Y Ichinose; N Nakasone; M Tanabe
Journal:  Microbiol Immunol       Date:  1986       Impact factor: 1.955

7.  Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels.

Authors:  P J Hitchcock; T M Brown
Journal:  J Bacteriol       Date:  1983-04       Impact factor: 3.490

8.  Identification of toxS, a regulatory gene whose product enhances toxR-mediated activation of the cholera toxin promoter.

Authors:  V L Miller; V J DiRita; J J Mekalanos
Journal:  J Bacteriol       Date:  1989-03       Impact factor: 3.490

9.  Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

Authors:  J D Clemens; D A Sack; J R Harris; F Van Loon; J Chakraborty; F Ahmed; M R Rao; M R Khan; M Yunus; N Huda
Journal:  Lancet       Date:  1990-02-03       Impact factor: 79.321

10.  Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.

Authors:  J D Clemens; D A Sack; J R Harris; J Chakraborty; P K Neogy; B Stanton; N Huda; M U Khan; B A Kay; M R Khan
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

View more
  48 in total

Review 1.  Bacterial outer membrane vesicles in disease and preventive medicine.

Authors:  Can M Unal; Viveka Schaar; Kristian Riesbeck
Journal:  Semin Immunopathol       Date:  2010-12-12       Impact factor: 9.623

2.  Vibrio cholerae-induced inflammation in the neonatal mouse cholera model.

Authors:  Anne L Bishop; Bharathi Patimalla; Andrew Camilli
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Rapid effects of a protective O-polysaccharide-specific monoclonal IgA on Vibrio cholerae agglutination, motility, and surface morphology.

Authors:  Kara J Levinson; Magdia De Jesus; Nicholas J Mantis
Journal:  Infect Immun       Date:  2015-02-09       Impact factor: 3.441

4.  A monoclonal antibody that targets the conserved core/lipid A region of lipopolysaccharide affects motility and reduces intestinal colonization of both classical and El Tor Vibrio cholerae biotypes.

Authors:  Kara J Levinson; Danielle E Baranova; Nicholas J Mantis
Journal:  Vaccine       Date:  2016-10-20       Impact factor: 3.641

Review 5.  New technologies in developing recombinant attenuated Salmonella vaccine vectors.

Authors:  Shifeng Wang; Qingke Kong; Roy Curtiss
Journal:  Microb Pathog       Date:  2012-11-08       Impact factor: 3.738

6.  Membrane vesicles of Clostridium perfringens type A strains induce innate and adaptive immunity.

Authors:  Yanlong Jiang; Qingke Kong; Kenneth L Roland; Roy Curtiss
Journal:  Int J Med Microbiol       Date:  2014-02-19       Impact factor: 3.473

7.  Proteomic analysis of Vibrio cholerae outer membrane vesicles.

Authors:  Emrah Altindis; Yang Fu; John J Mekalanos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-31       Impact factor: 11.205

Review 8.  Versatile effects of bacterium-released membrane vesicles on mammalian cells and infectious/inflammatory diseases.

Authors:  You-Jiang Yu; Xiao-Hong Wang; Guo-Chang Fan
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

9.  Immunity Provided by an Outer Membrane Vesicle Cholera Vaccine Is Due to O-Antigen-Specific Antibodies Inhibiting Bacterial Motility.

Authors:  Zhu Wang; David W Lazinski; Andrew Camilli
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

10.  Importance of antibodies to lipopolysaccharide in natural and vaccine-induced serum bactericidal activity against Neisseria meningitidis group B.

Authors:  Deborah H Schmiel; Elizabeth E Moran; Paul B Keiser; Brenda L Brandt; Wendell D Zollinger
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.